Work

Optimizing control of severe asthma contributes to cardiovascular prevention

Year: 2025

Type: article

Abstract: Although asthma deaths decrease with the dissemination and implementation of GINA guidelines advocating for ICS-containing regimen, long term outcomes of severe asthma are still hallmarked by impaired quality of life attributable not only to persistent daily symptoms and impaired lung function but mostly to recurrent exacerbations.1 Asthma exacerbations are now recognized as the primary outcome of most phase III pivotal trials dedicated to assess the benefits of new drugs in development. They are now better understood as the consequence of mostly virally-triggered infections leading to exaggerated and inappropriate type 2 inflammation and excessive airway bronchoconstriction.

Source: The Lancet Regional Health - Europe

DOI: 10.1016/j.lanepe.2025.101477

Authors: Olivier Cazorla, Arnaud Bourdin

Institutions: Centre National de la Recherche Scientifique, Inserm, Université de Montpellier, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Hôpital Arnaud de Villeneuve

Language: English

Topic: Asthma and respiratory diseases

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,930